FibroBiologics says Australia accepts patent application for CBD adjuvant therapy in degenerative disc disease

• FibroBiologics reported IP Australia accepted its patent application for cannabidiol as an adjuvant to fibroblast cell therapy in degenerative disc disease.
• Application No. 2020368344 outlines treatment methods combining cannabidiol with fibroblast cells, including differentiated cells intended to support disc regeneration.
• Claims also cover using cannabidiol to boost fibroblast regenerative activity, including higher growth-factor output such as IGF-1 or EGF-1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608200830PR_NEWS_USPR_____DA30163) on August 20, 2026, and is solely responsible for the information contained therein.